EP-0057 is under clinical development by Ellipses Pharma and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EP-0057’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EP-0057 overview

EP-0057 (NLG-207, CRLX-101) is under development for the treatment of solid tumors including epithelial ovarian cancer, peritoneal cancer, fallopian tube cancer, small-cell lung cancer, and metastatic castration-resistant prostate cancer (mCRPC). The drug candidate is administered intravenously. It acts by targeting hypoxia inducible factor 1 (HIF-1) alpha and topoisomerase I. It comprises the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer. The drug candidate is a poly-cyclodextrin-bis-cysteine-PEG3400-camptothecin-conjugate and it is developed based on cyclodextrin nanoparticle technology (CDP) (Cyclosert). It was also under development for the treatment of lymphoma, small cell lung cancer, non-small cell lung cancer, gastric cancer, esophageal cancer, adenocarcinoma of the gastroesophageal Junction, metastatic triple negative breast cancer, rectal cancer and metastatic renal cell carcinoma.

Ellipses Pharma overview

Ellipses Pharma is a drug development company focused on the advancement of innovative cancer treatments through the clinic. The company has developed a technology platform to access the best oncology drug assets for further investigation, analysis and clinical development. Ellipses Pharma provides a permanent source of capital for the development of cancer assets and conducts multiple oncology clinical trials in parallel supported by Scientific Affairs Group. The company is building relationships with research institutions, charitable bodies, pharmaceutical, and biotechnology companies, and outsourced development providers for delivering more treatment options in oncology. Ellipses Pharma is headquartered in London, England, the UK.

For a complete picture of EP-0057’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.